Volume 2 • Issue 1 • 2011

Review Article


Hormones and receptors in endometrial cancer

David Bender, Thomas Buekers and Kimberly Leslie

2011-07-28 Volume 2 • Issue 1 • 2011 • 1–25

Wnt/ß-catenin/Lef-1 signaling in the uterus and its implications in uterine gland formation and cancer development

Dawne N. Shelton and Michael J. Goodheart

2011-07-28 Volume 2 • Issue 1 • 2011 • 1–11

Article


Toward a microRNA signature of endometrial cancer

Eric J. Devor, Michael J. Goodheart and Kimberly K. Leslie

2011-07-28 Volume 2 • Issue 1 • 2011 • 1–7

Case Report


Positron emission tomography in detection of metastatic leiomyosarcoma in a postoperative patient: a case report

David B Engle, Linda M. Smiley, Scott L. Baum and Greg P. Wellman

2011-07-28 Volume 2 • Issue 1 • 2011 • 1–5

Diagnosis of endometrial cancer complicated by morbid obesity—a case report

Janna Girardi and Michael Goodheart

2011-07-28 Volume 2 • Issue 1 • 2011 • 1–5

Board Member Spotlight


Michael J. Goodheart, MD

Kristina W. Thiel

2011-07-28 Volume 2 • Issue 1 • 2011 • 1–2

Abstract


The relationship between vascularity, p53 gene mutations and distant metastatic disease in epithelial ovarian carcinoma

Janna Girardi, Megan Samuelson, Anna Button, Koen De Geest, David P. Bender, Amina Ahmed and Michael Goodheart

2011-07-28 Volume 2 • Issue 1 • 2011 • 1–2

Lymphoid Enhancing Factor 1 (Lef-1) overexpression in epithelial ovarian, fallopian tube and peritoneal cancer and associations with clinical factors

Aine Clements, David Engle, Dawne Shelton, Traci Neff, Soo Park, David Bender, Amina Ahmed, Koen De Geest, Anna Button, John F. Engelhardt and Michael Goodheart

2011-07-28 Volume 2 • Issue 1 • 2011 • 1–2

Combination therapy with mTOR and PI3 kinase inhibitors is broadly synergistic in a wide variety of endometrial cancer cells

Shujie Yang, Xue Xiao, Xiangbing Meng and Kimberly K. Leslie

2011-07-28 Volume 2 • Issue 1 • 2011 • 1–2

Comparison of P53 mutation status, primary cytoreductive surgical outcomes, and overall survival in patients with ovarian cancer

David Engle, Hubert Fornalik, Traci Neff, Anna Button, K Collins, Amina Ahmed, David Bender, Susan Lutgendorf and Michael Goodheart

2011-07-28 Volume 2 • Issue 1 • 2011 • 1–2

Zmiz1 is overexpressed in epithelial ovarian cancer and associated with p53 gene mutations

Niyati J Nadkarni, Laura M. Rogers, Megan Samuelson, Traci Neff, David P. Bender, Amina Ahmed, Koen De Geest, Anna Button, Adam Dupuy and Michael Goodheart

2011-07-28 Volume 2 • Issue 1 • 2011 • 1–2

MiR-888: A newly identified miRNA significantly over-expressed in endometrial cancers

Adriann M. Hovey, Eric J. Devor and Kimberly K. Leslie

2011-07-28 Volume 2 • Issue 1 • 2011 • 1–1

Knockdown of MTDH increases drug sensitivity to HDAC inhibitor and TRAIL combination treatment in endometrial cancer cells

Xiangbing Meng, Pavla Brachova, Shujie Yang, Zhi Xiong, Yuping Zhang and Kimberly K. Leslie

2011-07-28 Volume 2 • Issue 1 • 2011 • 1–2

H19/miR-675 non-coding RNA expression differentiates among cancers of the human endometrium.

Eric J Devor, Jill N. DeMik, Brandon M. Schickling, Michael J. Goodheart and Kimberly K. Leslie

2011-07-28 Volume 2 • Issue 1 • 2011 • 1–1

The combination of Paclitaxel and Gefitinib inhibits endometrial cancer cells by inducing mitotic catastrophe: proof of principle for dual therapy in endometrial cancer

Xiangbing Meng, Laura L. Laidler, Lina Albitar, Anna M. Holmes, Donghai Dai, Thomas E. Buekers, David P. Bender and Kimberly K. Leslie

2011-07-28 Volume 2 • Issue 1 • 2011 • 1–2

Extended Abstract


Long-term Outcomes Among Women With Cervical Cancer Treated from 1960-1987

Christopher Yopp, Jo Benda, Colleen Stockdale, Jami L Shepard and Amina Ahmed

2011-07-28 Volume 2 • Issue 1 • 2011 • 1–2